Introduction {#S1}
============

The tyrosine kinase family, including both receptor tyrosine kinases (RTK) and non-receptor tyrosine kinases, triggers a cascade of downstream signaling pathways that control the complex biological process of cells, including proliferation, cellular organization, and differentiation. In normal cells, RTK activity is induced by the tightly regulated interaction between receptor-ligands, receptor-proteins, and reduced by negative regulation of protein tyrosine phosphatases ([@B218]; [@B27]; [@B48]). For example, the tropomyosin-related kinase A (TrkA) receptor, which is activated via its ligand, nerve growth factor (NGF)-induced dimerization, contributes to the neuronal differentiation ([@B174]). Also, Platelet-derived growth factor (PDGF)-β-mediated activation of platelet-derived growth factor receptor (PDGFR) can activate intercellular pathways through complex formation between PDGFR and Src family tyrosine kinases ([@B102]). Moreover, the density-enhanced phosphatase 1 (DEP1) blocks the internalization of vascular endothelial growth factor receptor (VEGFR) 2 by inducing dephosphorylation of VEGFR 2 ([@B105]). However, dysregulation of RTKs (as identified in various human cancers) may result in their activation by ligand-dependent or independent autophosphorylation, gain-of-function mutations, and gene amplification-mediated overexpression ([@B218]; [@B27]; [@B48]). RTK activation promotes cell proliferation, increases cell migration, motility, and disseminating ability, and confers drug resistance ([@B175]; [@B88]; [@B47]). Hence, a variety of RTKs have been identified as therapeutic targets for anticancer drug development.

Notably, activation and overexpression of RTKs have been observed in Ewing sarcoma (ES), suggesting that tyrosine kinases may play key roles in the pathogenesis of ES. Clinical or preclinical inhibitors of tyrosine kinases have been developed and tested as molecular targeting therapy in ES ([@B62]; [@B71]). Herein, we explore recent advances in our understanding of the effects of tyrosine kinase activation in ES, particularly focusing on mechanisms by which tyrosine kinases are linked to the progression of ES. Determining molecular mechanisms through which tyrosine kinases influence the pathogenesis of ES may offer a novel strategy to treat ES, as well as to increase the efficacy of current therapeutics.

Ewing Sarcoma {#S2}
=============

Although ES has a low incidence (accounting for less than 10% of human malignancies), it is the second most common round cell malignancy occurring in the primary soft tissues and bones of children, adolescents, and young adults, with 12% of pediatric malignancies ([@B69]). Additionally, ES has been detected in the ribs, spine, skull, and bones of hands, arms, legs, feet, and pelvis ([@B71]). Overall, 75% of ES patients with a localized tumor have demonstrated improved survival through a combination of multi-agent cytotoxic chemotherapy and local-control measures (surgical resection and radiotherapy) ([@B16]). Notably, the 5-year overall survival (OS) in ES patients is 87.5% at 10 years and 79.2% at 20 years, with patient mortality reported as 68.9% ([@B36]). Approximately 20--25% of ES patients with local and distant treatment failure developed distant metastasis after completion of systemic and local treatment ([@B142]; [@B62]).

In another study, 30%--40% of ES patients presented local and distant recurrence, closely associated with poor prognosis. The 5-year survival rate of patients with metastases significantly decreases to less than 30%, and the most common recurrent sites include the bone (56.5%), lung (52.2%), brain (6.5%), and bone marrow (6.5%) ([@B159]; [@B157]; [@B62]). Furthermore, chemotherapy and radiotherapy can induce secondary malignant neoplasms, and these secondary malignancies worsen the survival rates in ES patients ([@B119]). In ES patients who underwent radiotherapy, local recurrence was observed in 30--40% of patients ([@B224]; [@B49]), after which the survival rate was significantly reduced to less than 20--25% ([@B6]; [@B160]).

A specific chromosomal translocation *t*(11;22) (q24;q12) occurs in ES ([@B41]), and this chromosomal translocation results in the generation of a chimeric EWS-FLI1 fusion protein, created by the fusion of the amino-terminal portion of the FET family gene *EWSR1* with the carboxyl-terminal DNA-binding domain of the ETS family gene, *FLI1*. Approximately 80--90% of patients with ES harbor the EWS-FLI1 fusion protein. This protein, as an aberrant transcription factor, is reportedly involved in the progression of ES ([@B41]; [@B23]; [@B125]). In the molecular diagnosis of ES, one key feature is the detection of translocation involving the *EWSR1* gene on chromosome 22 band q12 by fluorescent *in situ* hybridization (FISH)-based detection or using the RT-PCR method ([@B71]). Additionally, the fusion of EWSR1 to the DNA-binding domain of ERG results in the EWS-ERG protein, which demonstrates functions similar to EWS-FLI1 ([@B180]), and EWS-ERG has been identified in 12.3% of ES patients ([@B40]). EWS-ERG was detected in circulating tumor cells of ES patients with large tumors and has been correlated with reduced survival in these patients ([@B167]).

ES patients demonstrate a chromosomal abnormality as a prognostic indicator. In total, 77.6% (38/49), 26.5% (13/49), 26.5% (13/49), 26.5% (13/49), and 24.5% (12/49) of ES patients contained trisomy 8, 2, 5, 12, and 20, respectively. Specifically, trisomy 20 was closely associated with a worsened OS ([@B158]). Moreover, ES induces the upregulation of the CD99 protein and caveolin 1 (CAV1), as diagnostic markers. CD 99 is a single-chain type-1 membrane glycoprotein, highly expressed in 90--97% of ES patients ([@B10]; [@B157]; [@B116]). CAV1, another diagnostic immunomarker, is highly expressed in 96% of ES patients, and its upregulation is significantly associated with CD99 expression. Additionally, CAV1 is detected in CD99-negative ES patients ([@B116]).

For the successful treatment of ES patients, most protocols of multi-agent cytotoxic chemotherapy involve vincristine/ifosfamide/doxorubicin/etoposide (VIDE) administration ([@B91]). Furthermore, alternative multidrug chemotherapy protocols contain cyclophosphamide, topotecan, and etoposide. In standard-risk patients, the administration of vincristine/dactinomycin/ifosfamide/doxorubicin (VAIA) therapy presented no differences in the event-free survival (EFS) and OS hazard ratio when compared with VACA therapy (cyclophosphamide replacing ifosfamide). However, cyclophosphamide revealed a higher incidence of hematological toxicity. In high-risk patients who received chemotherapy including etoposide, the EFS and OS hazard ratio demonstrated a 17% and 15% reduction in the risk of an event or death relative to VAIA therapy, respectively ([@B149]). Moreover, the addition of vincristine/topotecan/cyclophosphamide (VTc) to the standard five-drug chemotherapy (vincristine/doxorubicin/cyclophosphamide/ifosfamide/etoposide \[VDCIE\]) presented better clinical benefits for ES patients. The addition of VTc to standard therapy demonstrated no toxicities, and in patients with ES, the 5-year OS and EFS were 88% and 79.5% when compared with standard 3-week cycles, respectively ([@B124]).

The Functional Role of Receptor Tyrosine Kinases in the Progression of ES and Its Inhibitors {#S3}
============================================================================================

Insulin-Like Growth Factor I Receptor (IGF-1R) and Its Inhibitors {#S3.SS1}
-----------------------------------------------------------------

Insulin-like growth factor I receptor-1 mediated IGF-1R activation induces proliferation, epithelial-mesenchymal transition (EMT), metastasis, drug resistance, and tumor recurrence ([@B112]). The promoter activity of IGF-1R is significantly activated by the binding of EWS-WT1 with the -331 to -40 region of the IGF-1R promoter in desmoplastic small round cell tumor (DSRCT), a malignant soft tissue sarcoma occurring in young children ([@B96]). This indicates that IGF-1R may promote the transcriptional expression of EWS fusion genes by inducing distinct cellular pathways involved in the pathogenesis of various types of cancer. In one study, IGF-1R was reportedly upregulated in all the tumor samples, including those from ES and synovial sarcoma patients, and inhibition of the IGF-1R signaling pathway resulted in a loss of the invasive ability of ES cells ([Figure 1](#F1){ref-type="fig"}; [@B172]; [@B213]; [@B12]). Another report revealed that IGF-1R was upregulated in 93% of ES patients ([@B132]; [Table 1](#T1){ref-type="table"}). Additionally, IGF-1R activation is required for the EWS-1/FLI1-mediated transformation of ES cells ([@B194]). The sub-cellular localization of IGF-1R is associated with the poor survival observed in ES patients. Furthermore, nuclear localization of IGF-1R markedly increases prolonged progression-free survival (PFS) and OS in ES patients when compared with the cytoplasmic localization of IGF-1R ([@B12]; [Table 1](#T1){ref-type="table"}).

![Induced activation of IGF-1R facilitates the survival, metastasis, and chemoresistance in Ewing sarcoma (ES) by activating downstream signaling pathways. IGF/IGF-1R enhances the pathogenesis of ES by upregulating EWS-FLI-1 and VEGFR via the activation of the RAS/MAPK/ERK and PI3K/AKT signaling pathways. Additionally, IGF-1R is degraded by MDM2 and β-arrestin-1. IGF-1R, Insulin-like growth factor 1 receptor; VEGFR, vascular endothelial growth factor; MDM2, murine double minute-2.](fcell-08-00613-g001){#F1}

###### 

Involvement of tyrosine kinases in Ewing sarcoma.

  **Tyrosine kinase**                                                                                                                                     **Status**                                  **Methods**                     **Detection**                           **References**
  ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------- ------------------------------- --------------------------------------- ------------------------
  Insulin-like growth factor 1 receptor (IGF-1R)                                                                                                          Overexpressed Overexpressed                 IHC IHC                         16/16 (60 − 100%) 28/30 (93%)           [@B12]; [@B132]
  Fibroblast growth factor receptors (FGFRs)                                                                                                              Overexpressed Overexpressed                 IHC/qRT-CR, IHC                 7/9 (77.8%) 61/136 (44.85%)             [@B93]; [@B2]
  Eph receptor A2 (EphA2)                                                                                                                                 Overexpressed                               IHC                             66/73 (90.4%)                           [@B61]
  c-kit stem cell receptor (CD117)                                                                                                                        Overexpressed Overexpressed Overexpressed   IHC IHC IHC                     11/17 (65%) 27/71 (38%) 22/31 (71%)     [@B179]; [@B3]; [@B45]
  Human epidermal growth factor receptor 2 (HER2) Human epidermal growth factor receptor 2 (HER4)                                                         Overexpressed Overexpressed                 IHC IHC                         18/113 (32%) 45/78 (57.7%)              [@B173]; [@B126]
  MET anaplastic lymphoma kinase (ALK)                                                                                                                    Overexpressed Overexpressed                 IHC IHC                         43/50 (86%) 41/59 (70%)                 [@B58]
  Platelet-derived growth factors receptor (PDGFR)β Platelet-derived growth factors receptor (PDGFR)α Platelet-derived growth factors receptor (PDGFR)β   Overexpressed Overexpressed Overexpressed   IHC qRT-PCR, IHC qRT-PCR, IHC   47/52 (90.4%) 10/19 (52%) 15/19 (79%)   [@B200]; [@B207]
  Protein tyrosine *kinase* (PTK) *Lyn*                                                                                                                   Overexpressed                               WB                              16/15 (86.7%)                           [@B72]
  FMS like tyrosine kinase 3 (*FLT3; CD135*)                                                                                                              Overexpressed                               RT-PCR                          17/19 (89.4%)                           [@B192]
  AXL receptor tyrosine kinase                                                                                                                            Overexpressed                               RT-PCR, IHC                     20/29 (69%)                             [@B57]
  Spleen tyrosine kinase (SYK)                                                                                                                            Activated                                   IHC                             14/35 (40%)                             [@B186]

IHC, Immunohistochemistry; qRT-PCR, Quantitative Real-time polymerase chain reaction; WB, Western blotting; RT-PCR, Real-time polymerase chain reaction.

Importantly, activation of IGF-1R signaling prevents the apoptosis of ES cells induced by the cytotoxic activities of anticancer drugs, such as doxorubicin, by activating phosphoinositide-3-OH kinase/AKT pathway ([@B195]) and enhancing the transformation of mouse fibroblasts through transcriptional induction of EWS-FLI1 via the PI3K/AKT-mediated upregulation of specificity protein 1 (SP1) transcription factor ([@B194]; [@B65]). Introduction of antisense IGF-1R decreased cell proliferation and tumor growth of ES cells *in vivo* and *in vitro* ([@B171]). Both *in vivo* and *in vitro*, the expression of the IGF-I receptor dominant-negative mutant in ES cells markedly reduced the growth rate, tumor formation, metastases, and chemoresistance against doxorubicin ([@B170]). Activation of IGF-1R by IGF-1 activates AKT and extracellular-signal-regulated kinases (ERK) 1/2 in ES cells. However, inhibition of RAS/MEK/MAPK activation failed to rescue the proliferation of ES cells induced by IGF-1 treatment, indicating that compensatory activation of the RAS/MEK/MAPK signaling pathway may inhibit only IGF-1R ([@B20]). Moreover, investigation of 56 ES patients receiving neoadjuvant chemotherapy for prognostic and therapeutic purposes demonstrated positive correlations between the levels of IGF-1R and phospho-ERK (*ρ* = 0.286, *p* = 0.031, respectively), IGF-1R and phospho-AKT (*ρ* = 0.269, *p* = 0.045, respectively), phospho-AKT and phospho-ERK (*ρ* = 0.460, *p* = 0.000, respectively), and phospho-ERK and phospho-mTOR (mammalian target of rapamycin) (*ρ* = 0.273, *p* = 0.038, respectively) ([@B201]). Furthermore, activation of IGF-1R and mTOR and expression of EWS-FLI1 were strongly correlated with high BMI-1 levels, which is overexpressed in 80% of ES patients and induces tumor growth in a xenograft model ([@B203]).

Clinical and preclinical IGF-1R inhibitors are being utilized as monotherapy or in combination with anti-neoplastic inhibitors to inhibit ES ([Table 2](#T2){ref-type="table"}). Internalization and ubiquitination of IGF-1R are required for enhancing the sensitivity of the IGF-1R inhibitor. Both clathrin- and caveolin-1 (CAV-1)--dependent endocytosis-mediated internalization of IGF-1R are localized in the cytoplasm via complex formation between IGF-1R and both clathrin and CAV-1. Inhibition of clathrin- and CAV-1-dependent IGF-1R internalization following treatment with endocytosis inhibitors such as chlorpromazine (CPMZ) and methyl-β-cyclodextrin (MCD) rendered ES cells more sensitive to NVP-AEW541, an IGF-1R inhibitor ([@B123]). PU-71, heat shock protein (HSP) 90 inhibitor, is currently under evaluation for patients with solid metastatic tumors, lymphoma, and myeloma ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT01393509, NCT03166085, and NCT01269593). PU-71 treatment markedly suppressed the survival and metastatic ability of ES cells through inhibition of IGF-1R, AKT, and pERK activation, as well as downregulation of RAF-1, c-MYC, c-KIT, IGF1R, hTERT, and EWS-FLI1 expression. Furthermore, the combination of PU-71 and bortezomib, as a proteasome inhibitor, significantly inhibited tumor growth and metastasis in ES xenograft models ([@B9]).

###### 

Efficacy of Insulin-like growth factor 1 receptor (IGF-1R) inhibitors in combination with other inhibitors in treating Ewing sarcoma.

  **Target of inhibitors**   **Inhibitor/Clinical trial identifier**                               **Drug Type**   **Phase**      **Efficacy of Drug**                                                                                                                                                                               **References**
  -------------------------- --------------------------------------------------------------------- --------------- -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  IGF-1R                     Teprotumumab/NCT00642941                                              mAb             Phase 2        1% of patients had SD, and 8.7% of patients achieved PR                                                                                                                                            [@B146]
  IGF-1R                     Figitumumab/NCT00560235                                               mAb             Phase 1/2      23% of patients had SD and 14.2% of patients achieved PC                                                                                                                                           [@B92]
  IGF-1R + mTOR              IMC-A12 + Temsirolimus/NCT00678769                                    mAb + Chem      Phase 1        50% of patients showed no disease but exhibited both mTOR and RAS/Raf/ERK activation                                                                                                               [@B184]
  IGF-1R                     BMS-536924                                                            Chem            Cell line      This treatment induced sensitivity against ES cells by suppressing activation of IGF-1R and RPS6                                                                                                   [@B153]
  EWS-FLI1 + IGF-1R          Trabectedin + OSI-906                                                 Chem            Cell line/Xg   This treatment synergistically increased cytotoxic effects in ES cells                                                                                                                             [@B8]
  IGF-1R + CDK4/6            OSI-906 + Palbociclib                                                 Chem            Xg             This combination markedly decreased tumor growth                                                                                                                                                   [@B136]
  IGF-1R                     Picropodophyllin/NCT01721577                                          Chem            Phase 1        This treatment inhibited cell survival by suppression of IGF-1R-mediated AKT activation                                                                                                            [@B7]
  IGF-1R + mTOR              Cixutumumab + Temsirolimus/NCT01614795                                Chem            Phase 2        31% of patients achieved SD for more than 5 months, and 29% of patients had more than 20% of tumor regression                                                                                      [@B138]
  IGF-1R                     Ganitumab/NCT00563680                                                 mAb             Phase 2        49% of the ORR demonstrated SD with a good response, and 6% of the ORR exhibited PR                                                                                                                [@B189]
  IGF-1R + CDK4/6            Ganitumab + Palbociclib/NCT04129151                                   mAb + Chem      Phase 2        This therapeutic strategy is currently under evaluation                                                                                                                                            UE
  IGF-1R                     Metformin                                                             Chem            Cell line/Xg   Metformin significantly induced cell death of ES cells                                                                                                                                             [@B140]
  IGF-1R                     allogeneic NK cell infusion and adoptive T-cell therapy/NCT02409576   IT              Phase 1/2      NK cell immunotherapy is now under evaluation, and IGF-1R-CAR-T and ROR1-CAT-T cells derived from sarcoma patients significantly increased the cytotoxicity of ES cells and reduced tumor growth   [@B85]

IGF-1R, Insulin-like growth factor 1 receptor; mAb, monoclonal antibody; Chem, Chemical; SD, Stable disease; PR, Partial response; CR, Complete recovery; ORR, Objective recovery rate; UE, Under Evaluation; Xg, Xenograft; IT, Immunotherapy.

In patients with ES, IGF-1R inhibitors in combination with mTOR inhibitors could enhance the clinical benefits of therapy. The deletion of phosphatase and tensin homolog on chromosome 10 (PTEN) was identified in 25% of the ES patients, consistent with the *PTEN* deletion in ES cells, which eventually resulted in the reduced sensitivity to IGF-1R inhibitors, including NVP-AEW541 and OSI-906, and activation of the AKT pathway in the ES cells. Interestingly, the loss of PTEN expression in ES cells potentiated the autophagic response by increasing responsiveness to temsirolimus, a mammalian target of rapamycin (mTOR) inhibitor ([@B148]; [@B143]).

In ES cells, constitutive activation of IGF-1R and its downstream PI3K/AKT/mTOR pathway results in the resistance to bromodomain and extra-terminal domain (BET) inhibitors. However, combining IGF-1R inhibitors with BET inhibitors, or mTOR inhibitors, presents a synergistic effect on the inhibition of survival and tumor growth of ES cells both *in vivo* and *in vitro* ([@B117]). Additionally, IGF-1R inhibitor-resistance in ES cells was closely correlated with the activation of IRS1, PI3K, signal transducer and activator of transcription (STAT)-3, Src, and p38 MAPK. Both IGF-1R inhibitor and mTOR inhibitor treatment significantly reduced the tumor growth in ES xenografts through inhibition of IGF-1R/PI3K/AKT/mTOR, and other signaling pathways, including MEK1/2, JAK/STAT3, TGF-β, and G-protein coupled receptors ([@B104]). Treatment with BMS-536924, an IGF-1R inhibitor, induced cell death, and cell cycle arrest in ES cells by suppressing activation of IGF-1R and RPS6. However, activation of MST1R, which is highly expressed in 50% of ES patients, blocked the BMS-536924-mediated cell death of ES cells by activating RPS6, a distal IGF1R effector. Treatment with rapamycin, a mTOR1 inhibitor, markedly reduced RPS6 activation in BMS-536924-resistant ES cells, inducing cell death in BMS-536924-resistant ES cells ([@B153]). A combination of IMC-A12 (an IGF-1R) and rapamycin presented an enhanced therapeutic effect, demonstrating a prolonged response when compared with IMC-A12 treatment alone ([@B100]). Moreover, patients who acquired resistance to a combination of IMC-A12 and temsirolimus (an mTOR inhibitor) ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT00678769) revealed activation of mTOR, STAT3, and AKT pathways after receiving this combination treatment ([@B184]).

Treatment with TAE226, a dual inhibitor of IGF-1R and focal adhesion kinase (FAK), significantly suppressed proliferation and tumor growth of ES cells *in vivo* and *in vitro* by inducing apoptosis by inhibiting IGF-1R, FAK, and AKT activation when compared with PF-562,271, a dual inhibitor of FAK and proline-rich tyrosine kinase 2 (Pyk2). TAE226 inhibited the activation of the brain-derived neurotrophic factor (BDNF), epidermal growth factor receptor (EGFR), and transforming growth factor (TGF) -β signaling pathways, regulated by IGF-1R and FAK ([@B134]). Loss of CDK4 as an ES-selective dependency gene markedly reduced the growth of ES cells, but IGF-1R overexpression promoted the acquisition of resistance against the cyclin-dependent kinase (CDK) 4/6 inhibitor. Combination treatment with an IGF-1R inhibitor and CDK4/6 inhibitor demonstrated synergistic activity by inhibiting tumor growth and survival of ES cells *in vivo* and *in vitro* through the suppression of PKC/AKT/mTOR and activation of RB ([@B73]). Furthermore, AZD3463, as a dual inhibitor of anaplastic lymphoma kinase (ALK) and IGF-1R, in combination with vorinostat, a histone deacetylase inhibitor, and temozolomide, an alkylating agent, induce cell death in ES cells by significantly inhibiting the activation of STAT3/AKT activation ([@B162]).

N-linked glycosylation of IGF-1R is essential for its translocation to the cell surface. Treatment of IGF-1R with glycosylation inhibitors, including tunicamycin and the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, lovastatin, reduced the activation and expression of IGF-1R, subsequently reducing the survival of ES cells ([@B67]). Treatment with RITA (reactivating p53 and inducing tumor apoptosis), a furanic compound, significantly suppressed cell growth and metastatic potential in ES cells via RITA-induced downregulation of IGF-1R as a transcriptional target of p53, as well as the degradation of IGF-1R by RITA-mediated upregulation of murine double minute-2 (MDM2) ([@B43]).

Treatment with teprotumumab (R1507), an anti-IGF-1R antibody, completely inhibited the growth of ES cells by suppressing activation of the IGF-1R/IRS-1/AKT axis ([@B80]). Following this treatment, the complete response rate was 10% of the objective response rate (ORR), and the median OS was 7.6 months, indicating that teprotumumab treatment is well-tolerated. Teprotumumab has an extremely safe toxicity profile in patients with recurrent or refractory ES ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT00642941) ([@B146]); however, it was reportedly inactive in patients presenting other types of sarcoma ([@B147]). In January 2020, the FDA-approved teprotumumab as the first drug for the treatment of patients with thyroid eye disease ([@B198]).

Figitumumab, a monoclonal anti-IGF-1R antibody, significantly reduces cell proliferation of ES cells by suppressing signaling pathways downstream to IGF-1R, including MAPK/ERK and PI3K/AKT pathways ([@B219]). Additionally, figitumumab treatment increased β-arrestin1 expression, which inhibited the survival of ES cells by decreasing IGF-1R expression via β-arrestin1-mediated ubiquitination, following the formation of the IGF-1R/β-arrestin1 complex ([@B219]). Figitumumab was evaluated in ES patients with metastases in phase 1/2 clinical trials. Reportedly, the complete response rate (disease stabilization) and partial response rate were 23% and 14.2% of the ORR, respectively. Additionally, in a phase 2 trial, figitumumab showed prolonged OS in ES patients ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT00560235) ([@B92]).

Furthermore, human monoclonal antibodies have been developed and evaluated for the treatment of solid tumors, including ES. As cixutumumab (an IGF-1R inhibitor) monotherapy demonstrated limited single-agent activity in a phase 2 trial ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT00831844) in ES patients, a combination of cixutumumab and temsirolimus was used, revealing that 31% of patients achieved stable disease (SD) for more than 5 months and 29% of patients demonstrated more than 20% tumor regression ([@B138]). A phase 2 clinical trial of ganitumab ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT00563680), a monoclonal anti-IGF-1R antibody, revealed its well-tolerated and safe profile. In the trial, patients with a 49% ORR demonstrated SD with a good response, while those with 6% ORR exhibited partial response ([@B189]). However, IGF-1R-directed monotherapies, including figitumumab, cixutumumab, teprotumumab, ganitumumab, or cixutumumab, in combination with temsirolimus, presented only modest efficacy in ES patients ([@B204]).

Currently, ganitumab monotherapy and a combination of palbociclib and ganitumab are under evaluation in phase 3 clinical trial as add-on therapy in patients with metastatic ES ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02306161 and NCT04129151). Although anti-IGF-1R antibodies have been tested in clinical trials, these antibodies remain unapproved by the FDA.

Trabectedin (ET-743), an FDA-approved drug for the treatment of unresectable or metastatic liposarcoma or leiomyosarcoma ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: ET743-SAR-3007 and NCT01343277) ([@B68]; [@B17]), demonstrates antitumor activity against ES cells by inhibiting the binding of EWS-FLI1 to the promoter of its target genes, *TGF*β*R2* and *CD99.* Additionally, trabectedin in combination with OSI-906 (linsitinib), an IGF-1R inhibitor, markedly increases cytotoxic effects in ES cells by synergistically interacting with the anti-IGF-1R antibody or trabectedin ([@B8]). Notably, ES patients with a genetic alteration owing to the *CDKN2A/B* loss and a *FUS-ERG* fusion-derived orthotopic xenograft (PDOX) model exhibited a similar histomorphological appearance. A combination of OSI-906 and Palbociclib (a CDK4/6 inhibitor) markedly decreased tumor growth in a PDOX model by suppressing the CDK4/6 and IGF-1R pathways ([@B136]).

In a phase − clinical trial for picropodophyllin (AXL1717), a novel IGF-1R inhibitor, performed in patients with relapsed malignant astrocytomas, 44% of patients demonstrated prolonged SD for 12 months ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT01721577) ([@B7]). Picropodophyllin inhibits cell survival in ES cells by suppressing IGF-1R-mediated AKT activation ([@B210]).

Metformin (1,1-dimethyl biguanide hydrochloride) is an FDA-approved drug indicated for the treatment of type 2 diabetes, reducing glucose concentration by inhibiting mitochondrial respiration and mitochondrial glycerophosphate dehydrogenase ([@B60]). Recently, metformin was assessed in combination with chemotherapeutic drugs and it reportedly inhibited the mTOR pathway via suppression of IGF-1R activation, by decreasing the levels of insulin-like growth factor (IGF) ([@B51]). Metformin, in combination with 5-fluorouracil and oxaliplatin (FuOX), induced cell death in chemoresistant colon cancer cells by suppressing cancer stem cells (CSC) characteristics, STAT3, and NF-κB activation ([@B140]) and suppressing STAT3 and NF-κB activation ([@B113]; [@B55]; [@B217]; [@B53]). ES demonstrates high metabolic and glycolytic activity, and a combination of 2-deoxy-D-glucose (2DG) with metformin induces cell death in ES via metformin-induced inhibition of mitochondrial respiration and 2DG-induced inhibition of aerobic glycolysis ([@B35]). Furthermore, a combination of metformin and imatinib reduced the proliferation of ES cells by inducing cell cycle arrest and inhibiting tumor growth and metastasis in mice ([@B139]).

Natural killer (NK) cells and chimeric antigen receptor (CAR)-based immunotherapy for adoptive cellular immunotherapy have been applied for the effective treatment of ES, inducing the activation and expansion of NK cells by inhibiting IGF-1R expression, without affecting the immunophenotypes of NK cells and their degranulation response to ES cells, and subsequently maintaining potent antitumor effects against ES cells ([@B85]). As NK cell therapy has reported safety and efficacy, as well as good tolerance, in leukemia patients, clinical trials of allogeneic NK cell infusions in patients with metastatic ES and high-risk rhabdomyosarcoma (RMS) are currently ongoing ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02409576). IGF-1R and tyrosine kinase-like orphan receptor 1 (ROR1) are highly expressed in ES cells, and the application of adoptive T-cell therapy using IGF-1R-CAR-T and ROR1-CAT-T cells derived from sarcoma patients significantly increases ES cell death and reduces tumor growth of sarcoma xenografts ([@B81]).

Fibroblast Growth Factor Receptors (FGFRs)/Their Ligand (FGF) and Its Inhibitors {#S3.SS2}
--------------------------------------------------------------------------------

Activation of FGFRs by their ligand, FGF, promotes tumor progression through the activation of the PI3K/AKT, RAS-MAPK, and JAK/STAT signaling pathways ([Figure 2](#F2){ref-type="fig"}) ([@B13]). FGFR1 is highly expressed in ES cells, and moderate-to-high levels of FGFR1 activation were detected in 77.8% of ES patients. FGF treatment induces metastasis in ES cells by activating the PI3K/Rac1 pathway ([Table 1](#T1){ref-type="table"}; [@B93]). Another report revealed that FGFR1 was upregulated in 54.3% of ES patients ([Table 1](#T1){ref-type="table"}; [@B2]), inducing marked EWS-FLI1 upregulation ([@B66]) compared with other ligands, such as insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF)-BB, hepatocyte growth factor (HGF), epidermal growth factor (EGF), and TGF-β1. However, suppression of FGFR activation, by the addition of the FGF-neutralizing antibody, leads to a marked reduction in EWS-FLI-1 expression ([Figure 1](#F1){ref-type="fig"}; [@B66]). Expression of SPRY1, a negative feedback inhibitor of the FGFR-activated RAS/MAPK/ERK signaling pathway, was markedly reduced by EWS-FLI1; however, its upregulated expression suppressed cell proliferation and aggressiveness of ES cells by downregulating EWS-FLI1 through the inhibition of RAS/MAPK/ERK activation ([Figure 1](#F1){ref-type="fig"}; [@B32]).

![Contribution of tyrosine kinases in the induction of survival, metastasis, and chemoresistance in Ewing sarcoma (ES) through the activation of downstream signaling pathways. Tyrosine kinase receptors and non-receptor tyrosine kinase, including HGF/MET, EphA2, c-kit, HER2/3/4, ALK, PDGFR/PDGF, JAK/STAT, SFK, PYK22, FLT3, AXL, and SYK are involved in the pathogenesis of ES by blocking feedback inhibition of RAS/MAPK/ERK by SPRY1 and upregulation of EWS-FLI-1 through the activation of RAS/MAPK/ERK, PI3K/AKT, and JAK/STAT3 signaling pathways. Additionally, Src activation leads to cell proliferation and metastasis of ES cells via induction of Rac1 activity through the activation of p38 MAPK, FAK, and PI3K/AKT signaling pathways. HGF, hepatocyte growth factor; EphA2, erythropoietin-producing hepatoma receptor A2; STAT3, signal transducer and activator of transcription-3; FAK, focal adhesion kinase; MAPK, mitogen-activated protein kinase; JAK, Janus kinase.](fcell-08-00613-g002){#F2}

An FGFR1 mutant (FGFR1 N546K), which occurs in the tyrosine kinase domain of FGFR1 as a result of an activating mutation, has been identified in pineal tumor, peritoneal sarcoma, pilocytic astrocytoma, gastrointestinal stromal tumors (GISTs), pheochromocytomas, liposarcoma, breast sarcoma, malignant peripheral nerve sheath tumor, neuroblastoma, paraganglioma, and glioblastoma ([@B110]; [@B89]; [@B78]; [@B193]; [@B141]). This mutant has also been identified in 0.02% (1/50) of ES patients, and 31.7% (23/50) of ES patients demonstrated a gain of copy number of FGFR1. FGFR1 N546K mutation promotes the constitutive activation of FRFR1 ([@B110]; [@B97]), and the introduction of FGFR1 N546K in NIH3T3 cells significantly increased the proliferation and the aggressiveness of cells relative to wild-type FGFR1 ([@B2]). Furthermore, FGFR4 (FGFR4 G388A) was identified in ES and breast cancer patients, but its functional role remains unclear. Further, FGFR3 (K650E), a product of an activating mutation, was identified in glioma, non-small-cell lung carcinoma (NSCLC), ES, and liposarcoma (LPS), and correlated with poor survival in patients with LPS ([@B78]; [@B111]; [@B108]).

[Table 3](#T3){ref-type="table"} shows preclinical or clinical trials using FGFR inhibitors, with or without anti-neoplastic inhibitors as targeted therapeutics against ES. Treatment with FGFR inhibitors (PD173074 \[PD-74\], PD166866 \[PD-66\], SU5402 \[SU54\], and NVP-BGJ398 \[BG-98\]) reduced the proliferation of ES cells; PD173074 in particular suppressed the proliferation of ES cells and tumor formation in mice ([@B32]). Additionally, treatment with ponatinib, a known FGFR inhibitor targeting FGFR1, elicited a good response by suppressing glucose uptake in ES tumors ([@B2]).

###### 

Efficacy of tyrosine kinase targeting inhibitors in combination with other inhibitors in treating ES.

  **Target of inhibitors**                      **Inhibitor/Clinical trial identifier**             **Drug Type**     **Phase**                   **Efficacy of Drug**                                                                                                                                                             **References**
  --------------------------------------------- --------------------------------------------------- ----------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------
  VEGFR2                                        Apatinib/2017PHB176-03                              Chem              Phase 1/2                   62.5% of patients showed a PR, and 19.6% of patients had SD                                                                                                                      [@B212]
  VEGFR1, 2, 3                                  Axitinib/NCT02164838                                Chem              Phase 1                     31.25% of patients achieved SD, and 0.07% of patients had PR                                                                                                                     [@B64]
  VEGFR1, 2, 3 + PD-1                           Axitinib + Pembrolizumab/NCT02636725                Chem + mAb        Phase 2                     28% of patients achieved SD, and 25% of patients achieved PR                                                                                                                     [@B209]
  VEGFR1, 2, 3                                  Pazopanib/NCT00753688                               Chem              Phase 3                     67% of patients achieved SD, and 6% of patients had CR                                                                                                                           [@B202]
  VEGF + inhibiting DNA and protein synthesis   IFN-β + ifosfamide                                  cytokine + Chem   Cell line/Xg                These treatments inhibited tumor growth of ES cells                                                                                                                              [@B165]
  VEGFR2 + IGF-1R                               Adnectin + AT580Peg40                               Chem              Xg                          This treatment effectively reduced 83.4% of tumor growth in xenografts                                                                                                           [@B1]
  Glycosylation + HMG-CoA reductase             Tunicamycin + lovastatin                            Chem              Cell line/Xg                These treatments reduce the activation and expression of IGF-1R and reduced the survival of ES cells                                                                             [@B67]
  HER2                                          HER2-CAR-T-cell/NCT00902044                         IT                Phase 1                     75% of patients had a residual tumor removed, 82.3% of patients showed more than 90% prominent necrosis, and the median survival of patients markedly increased to 10.3 months   [@B4]
  FLT3                                          Midostaurin                                         Chem              Cell line/Xg                Suppressed the survival and tumor formation of ES cells in xenograft                                                                                                             [@B25]
  FLT3 + IGF-1R                                 Midostaurin + BMS-754807 or OSI-906                 Chem              Cell line                   This combination presented a synergistic effect on the inhibition of metastatic ability and proliferation of ES cells                                                            [@B154]
  MET                                           Cabozantinib/NCT02243605                            Chem              Phase 2                     49% of patients presented SD, and 22% of patients had a PR                                                                                                                       [@B84]
  HGF + GD2                                     Rilotumumab + GD2-CAR-T cells                       mAb               Cell line/Xg                This combination significantly reduced tumor growth and metastasis of xenografts                                                                                                 [@B29]
  PDGFR                                         Linifanib                                           Chem              Cell line/Xg                Linifanib inhibited cell proliferation, tumor growth, and metastases of ES cells                                                                                                 [@B82]
  PDGFR + topoisomerase2                        Olaratumab + doxorubicin/NCT02451943                Chem              Phase 3                     This treatment did not produce clinical benefits in patients with soft tissue sarcoma                                                                                            [@B197]
  FGFRs                                         PD173074                                            Chem              Cell line/Xg                PD173074 suppressed the proliferation of ES cells and tumor formation                                                                                                            [@B32]
  FGFRs                                         Rogaratinib/NCT01976741, NCT03410693, NCT03473756   Chem              Phase 1 Phase 2/3 Phase 1   Rogaratinib reduced proliferation in various cancer types but did not show any evidence of cancer reduction in ES patients in preclinical or clinical trials                     UE
  FGFRs                                         Ponatinib                                           Chem              Cell line                   Ponatinib suppressed the proliferation of ES cells                                                                                                                               [@B2]
  FGFRs                                         PD166866, SU5402, NVP-BGJ398                        Chem              Cell line                   These inhibitors suppressed the proliferation of ES cells                                                                                                                        [@B32]
  FGFRs                                         Erdafitinib/NCT02365597                             Chem              Phase 2                     2.3% of bladder patients had CR, and nearly 30% showed PR. This study is now recruiting ES patients                                                                              [@B130]
  AXL                                           Bemcentinib + vincristine                           Chem              Cell line                   Reduced cell viability and migration                                                                                                                                             [@B57]
  JAK1/2                                        AZD1480                                             Chem              Cell line/Xg                AZD1480 inhibited growth and tumor formation of ES cells in xenograft                                                                                                            [@B214]
  STAT3                                         LY5                                                 Chem              Cell line/Xg                LY5 markedly decreased the cell viability of sarcomas                                                                                                                            [@B216]

mAb, monoclonal antibody; Chem, Chemical; SD, Stable disease; PR, Partial response; CR, Complete recovery; ORR, Objective recovery rate; UE, Under Evaluation; Xg, Xenograft; IT, Immunotherapy; VEGFR, a vascular endothelial growth factor; FGFR, fibroblast growth factor receptors; JAK, Janus kinase; STAT3, signal transducer and activator of transcription; PDGFR, Platelet-derived growth factor receptor; HGF, hepatocyte growth factor; FLT3, FMS like tyrosine kinase 3 receptor; IFN-β, interferon beta; GD, Disialoganglioside.

In preclinical or clinical trials, rogaratinib, an ATP-competitive inhibitor of FGFR1-4, failed to demonstrate any antitumor activity in ES conducted both *in vitro* or *in vivo*. However, rogaratinib potently inhibited the kinase of FGFR1-4 in various cancers ([@B33]; [@B70]). These results support the inhibitory activity of rogaratinib, which is currently undergoing phase 2/3 clinical trials ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT01976741, NCT03410693, NCT03473756).

In April 2019, a clinical trial investigated FDA-approved erdafitinib, the first targeted therapy for the treatment of patients with metastatic bladder cancer with FGFR2 or FGFR3 mutations or gene fusions. Treatment with erdafitinib ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02365597) demonstrated an ORR of 32.2%, with 2.3% of these patients eliciting a complete response and nearly 30% showing partial response ([@B130]). Erdafitinib, as well as rogaratinib, exhibited antitumor activity against ES *in vitro* or *in vivo* in non-clinical studies. Clinical trials for the same are currently ongoing in patients with ES (NCT03210714).

Human Epidermal Growth Factor Receptors and Its Inhibitors {#S3.SS3}
----------------------------------------------------------

Human epidermal growth factor receptors (HERs; ERBBs) have been identified as inducers of ES ([Figure 2](#F2){ref-type="fig"}). HER2 (ERBB2) is overexpressed in various human cancers and is associated with poor patient survival ([@B129]). Additionally, HER2 is upregulated in 16% of ES patients and 83% of ES cell lines, and this upregulation is associated with a reduced survival rate in patients. Moreover, in 78% of ES patients, HER2 expression was associated with P-glycoprotein expression ([Table 1](#T1){ref-type="table"}; [@B173]). Furthermore, HER2 expression is associated with the tumorigenicity of ES and is overexpressed in ES cells, conferring resistance against topoisomerase II-targeting anticancer drugs, including etoposide and adriamycin. However, treatment with adenovirus early region 1A (E1A) or adenovirus-E1A therapy markedly decreased tumor formation in mice and enhanced sensitivity to etoposide and adriamycin by downregulating HER2 and upregulating topoisomerase IIα ([@B222]; [@B220]).

Human epidermal growth factor receptor 3 plays a crucial role in the progression of cancer as an inducer of chemoresistance, through heterodimerization with other HER receptors or through ligand binding ([@B18]). In ES patients, analysis of RTK expression profiles revealed that HER3 (ERBB3) is widely expressed; however, EGFR, its heterodimer-partner, demonstrated low-level expression in ES patients. Reportedly, the expression of HER3 is associated with reduced survival in ES patients ([@B152]).

The expression of HER4, a member of the EGFR family, is associated with ES progression. HER4 is strongly expressed in metastatic ES cells, 57.7% of primary ES patients, and 78.9% of metastatic ES patients, relative to primary ES patients. Treatment with lapatinib and a pan-ErbB inhibitor reduced the proliferation and metastatic potential of ES cells ([Table 1](#T1){ref-type="table"}; [@B127]; [@B126]). Moreover, HER4 enhanced the invasiveness of metastatic ES cells and increased their metastases *in vivo* by increasing Rac1 GTPase activity by activating the PI3K/AKT and FAK pathways ([@B127], [@B126]). Expression of microRNA (MiR)-193b suppressed anchorage-independent growth in ES cells by downregulating HER4 as its direct target ([@B131]).

HER2 chimeric antigen receptors and lapatinib (as a HER2 and HER4 inhibitor) have been evaluated in the treatment of solid tumors, including ES. HER2-specific chimeric antigen receptor (HER2-CAR) T-cells from healthy donors markedly reduced the proliferation of HER2-positive medulloblastoma cells, and HER2-CAR-T-cells from HER2-positive patients killed primary autologous HER2-positive medulloblastoma cells *in vivo* and *in vitro* by the inducing interferon (IFN)-γ production ([@B5]; [@B190]). Immunotherapy with antigen-specific T-cells (HER2-CAR-T-cells) was developed and tested in patients with metastatic or recurrent sarcoma in phase I/II clinical trial ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT00902044). Reportedly, 23.5% of patients receiving HER2-CAR-T-cells demonstrated SD for 3−14 months, and 75% of the patients who had residual tumors removed reported superior outcomes. Additionally, 82.3% of patients showed more than 90% necrosis of tumor cells, and the median survival of patients increased to 10.3 months ([Table 3](#T3){ref-type="table"}; [@B4]). Recently, FDA-approved neratinib, a new HER2 inhibitor for the treatment of patients with metastatic HER2-positive breast cancer ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT01808573) ([@B199]), decreased the risk of disease progression or death by 24% when compared with lapatinib or capecitabine, indicating that this inhibitor might provide a promising therapeutic option to improve host cytotoxicity and advance the clinical treatment of sarcoma. BDTX-189, osimertinib, and DZD9008, as novel ERBB inhibitors, are now under evaluation in phase 1/2 clinical trial in patients with solid tumors and NSCLC with mutations or alternations in HER2 or EGFR, respectively ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT04209465, NCT03586453, NCT03974022). However, these inhibitors have not been evaluated in ES.

MET/Hepatocyte Growth Factor (HGF), Anaplastic Lymphoma Kinase (ALK)/Pleiotrophin (PTN), or ALK/Midkine (MK) and Its Inhibitors {#S3.SS4}
-------------------------------------------------------------------------------------------------------------------------------

Activation of MET by HGF, and that of ALK by PTN or MK as its ligands, renders cancer more aggressive by activating multiple downstream pathways, including the PI3/AKT and ERK pathway ([@B74]; [@B50]). MET and ALK expression are involved in the pathogenesis of ES and synovial sarcoma ([@B44]; [@B58]). MET and ALK are strongly expressed in the cytoplasm of 86% ES patients, as well as in the membranes of 70% ES patients. Membranous MET expression and high ALK expression have been associated with poor survival in ES patients ([Table 1](#T1){ref-type="table"}; [@B58]). Using phosphoproteomic profiling, MET and ALK have been identified as novel targets of synovial sarcoma and are highly expressed in 58% and 14% of ES patients, respectively ([@B59]). In MET, missense mutations were identified in various cancer types, including ES. Patients with ES (11.1%) exhibited MET mutations such as T1010I and N375S; however, these mutations failed to demonstrate functional roles in ES ([@B87]). Additionally, these mutations have been observed in other cancers. In breast cancer, the MET T1010I mutation increased the metastatic potential of mammary epithelial cells by induction of AKT, MAPK, and STAT3 activation. Moreover, this mutant induced tumor formation in xenografts ([Figure 1](#F1){ref-type="fig"}; [@B115]). Furthermore, the MET N375S mutation modulates sensitivity and confers resistance to MET inhibitors, eventually suppressing MET inhibitor-mediated apoptosis in lung cancer cells ([@B101]).

[Table 3](#T3){ref-type="table"} shows preclinical and clinical trials using MET/HGF inhibitors with or without anti-neoplastic inhibitors as targeted therapeutics against ES. The FDA has approved crizotinib and cabozantinib (MET inhibitors) for patients with metastatic NSCLC, advanced renal cell carcinoma (RCC), and hepatocellular carcinoma (HCC), along with sorafenib or anti-angiogenic therapy. Crizotinib and cabozantinib have been tested in ES patients, and results indicated that they significantly reduced the viability of ES cells ([@B58]). Furthermore, 26% of ES patients treated with cabozantinib in a phase 2 trial demonstrated an objective response, 49% of patients showed SD, with 22% demonstrating a partial response for 6 months, thus indicating that cabozantinib possesses antitumor effects in ES patients ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02243605) ([@B84]).

Disialoganglioside (GD2) was upregulated in 20% of ES patients; a combination of GD2-CAR-T cells and all-*trans* retinoic acid (ATRA) significantly reduced tumor formation and prolonged survival in mice by suppressing the population of monocytic and granulocytic myeloid-derived suppressor cells (MDSCs) ([@B118]). In ES cells, HGF treatment significantly increased the tumor mass and metastasis. Moreover, a combination of GD2-CAR-T cells and rilotumumab, an anti-HGF antibody (AMG102), increased mice survival by suppressing tumor growth and metastasis ([@B29]).

Platelet-Derived Growth Factor Receptor (PDGFR)/Ligand (PDGF) and Its Inhibitors {#S3.SS5}
--------------------------------------------------------------------------------

PDGFR and its ligand (PDGF) are known therapeutic targets promoting proliferation and progression of cancer. Additionally, they are associated with the pathogenesis of ES, with PDGFRβ highly upregulated in ES cells (90.4%) and ES patients (79%) ([Table 1](#T1){ref-type="table"}; [@B200]). Activation of PDGFR by its ligand leads to the induction of motility in ES cells, by activation and induction of downstream targets, including PI3K/AKT and PLCγ ([Figure 2](#F2){ref-type="fig"}; [@B200]). Additional reports revealed that the α- and β-subunits of PDGFR were strongly expressed in tissues of ES patients. High levels of PDGFRα were observed in 100% of ES patients, with high levels of PDGFRβ observed in 79% of these patients. The knockdown of PDGFRβ in ES cells markedly reduced pulmonary metastases and reduced the size of primary chest wall ES tumors in an ES orthotopic xenograft model ([Table 1](#T1){ref-type="table"}; [@B207]). Bone marrow (BM) cells migrate to Ewing tumors and differentiate into the vascular smooth muscle/pericyte-like cells and endothelial cells expressing α-smooth muscle actin, desmin, and PDGFRβ, as well as a vascular endothelial growth factor (VEGFR)-2, and are subsequently associated with tumor vessel endothelium by PDFGRβ to support tumor vasculature ([@B155]).

[Table 3](#T3){ref-type="table"} shows PDGFR inhibitors in combination with or without other inhibitors for the treatment of ES. Functional crosstalk between PDGF-BB/PDGFR and stromal-derived growth factor 1α (SDF-1α)/C-X-C motif chemokine receptor 4 (CXCR4) requires enhanced cancer tumorigenesis and metastasis. Autocrine activation of PDGFRα induced tumorigenesis and metastasis in advanced skin squamous cell carcinomas (SCCs) via upregulation and secretion of SDF-1α, and then SDF-1/CXCR4 induced PDGFR-induced tumor cell invasion and metastasis ([@B22]). Furthermore, PDGFRβ inhibitors inhibited SDF-1α-induced chemotaxis in glioblastoma ([@B169]), and PDGF-BB induced CXCR4 and CXCR7 expression in pericytes ([@B211]).

Plerixafor (AMD3100), a CXCR4 antagonist, inhibits the BM-mediated tumor vasculature in ES by reducing PDGFRβ expression through the disruption of the SDF-1α/CXCR4 axis ([@B75]). CXCR4 was markedly upregulated in 64% of therapy-naïve ES patients and 47% of metastatic ES patients. SDF-1α (CXCL12), a ligand of CXCR4, was significantly increased in 95% of therapy-naïve and metastatic ES patients, and high CXCR4 expression was correlated with reduced survival in ES patients. ES cell proliferation was markedly increased following treatment with SDF-1α; however, the addition of plerixafor suppressed the proliferation of ES cells ([@B21]).

The efficacy of PDGFR inhibitors against ES has been evaluated. Linifanib (ABT-869) is a multitargeting tyrosine kinase inhibitor, which targets tyrosine kinases such as VEGFR, FLT3, and PDGFR. Linifanib is clinically active in patients with HCC, acute myeloid leukemia (AML), renal cell cancer, and NSCLC ([@B120]), inhibiting cell proliferation, tumor growth, and metastases in ES cells in xenografts by suppressing PDGFRβ and c-kit activation ([@B82]). PDGFRβ signaling-mediated pericyte recruitment facilitated the formation of the vascular-like structure by ES cells. However, treatment with imatinib- or a PDGFR-blocking antibody inhibited pericyte recruitment by suppressing PDGFRβ signaling, subsequently reducing tumor growth in ES cells *in vivo* ([@B191]).

Olaratumab, a PDGFRα inhibitor, delayed tumor formation in pediatric bone and soft tissue tumors in mice ([@B120]); however, a combination of olaratumab and doxorubicin ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02451943) failed to demonstrate clinical benefits in patients with soft tissue sarcoma ([@B197]). Instead, FDA-approved avapritinib (Ayvakit), another PDGFRα inhibitor, was investigated in clinical trials to treat patients with gastrointestinal stromal tumors (GISTs) presenting a PDGFRA D842V mutation, demonstrating a high response rate in 85% of patients. To date, no such clinical trials or preclinical examinations have been conducted in ES patients.

FMS Like Tyrosine Kinase 3 Receptor (*FLT3*; *CD135*) and Its Inhibitors {#S3.SS6}
------------------------------------------------------------------------

FMS like tyrosine kinase 3 (*FLT3*; *CD135*) is associated with poor clinical outcome in AML as it promotes cell proliferation and survival through the activation of the PI3K, RAS, and STAT3 signaling pathways ([@B182]), and is reportedly mutated in approximately 30% of AML patients ([Figure 2](#F2){ref-type="fig"}; [@B37]). These mutations lead to ligand-independent activation of FLT3 and its downstream pathway ([@B182]). The expression of FLT3 and its ligand was markedly upregulated in 89.4% of ES patients ([Table 1](#T1){ref-type="table"}; [@B192]).

[Table 3](#T3){ref-type="table"} shows the FLT3 inhibitors investigated for the treatment of ES. Midostaurin (PKC412), an FLT3 inhibitor, first approved by the FDA for treatment of AML patients with FLT3 mutations, suppresses the survival of ES cells and tumor growth in mice ([@B25]). A combination of midostaurin and IGF-1R/INSR inhibitors (BMS-754807 and OSI-906), identified through specific drug-drug interactions by a parallel combinatorial drug screen, has demonstrated a synergistic effect by inhibiting the metastatic ability and proliferation of cells through the suppression of PKC/AKT/mTOR and MAPK signaling pathways ([@B154]). Recently, gilteritinib (XOSPATA), a novel FLT3 inhibitor, was approved by the FDA for relapsed or refractory AML patients with FLT mutation ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT0241939). In AML patients receiving gilteritinib, the OS (9.3 vs. 5.6 months) and EFS (2.8 vs. 0.7 months) rates were significantly increased relative to the salvage chemotherapy group. Moreover, the number of patients with complete remission, with full or partial hematologic recovery, was 2.2 fold higher when compared with the salvage chemotherapy group ([@B150]). Treatment with gilteritinib may contribute to the better survival of ES patients, although its effects have not been investigated in ES patients.

Interferon-α/β Receptor (IFNAR)/Interferon-β (IFN-β) and IFN-β Based Therapy {#S3.SS7}
----------------------------------------------------------------------------

Treatment with IFN-β induces activation of p38 mitogen-activated protein kinase (MAPK) by increasing serine phosphorylation of STAT1, inducing apoptosis in ES cells by activating caspase-7 through the induction of interferon response factor (IRF)-1, thereby inducing cell cycle arrest in cooperation with p53 through transactivation of p21^*waf*1/CIP1^ ([@B163]).

As the FDA has approved IFN-based therapies for multiple sclerosis ([@B52]) in the U.S., treatment with IFN-β (Betaseron, Extavia), which has direct and indirect effects on tumor inhibition, will soon be utilized as a new therapeutic strategy for cancer ([@B24]). IFN-β demonstrates potential anti-tumorigenic effects on tumor cells, as well as immune-infiltrating cells ([@B137]), reducing tumor cell growth in various type of cancers through by suppressing PI3K/AKT activation, reducing anti-apoptotic proteins, including FLICE (FADD-like IL-1β-converting enzyme)-inhibitory protein (c-FLIP) and caspase-8, and activating the TNF-related-apoptosis-inducing ligand (TRAIL)-dependent pathway ([@B30]; [@B39]; [@B11]). Moreover, IFN-β repressed the acquisition of CSC characteristics ([@B46]); treatment with IFN-β markedly suppressed tumor growth in ES cells ([Table 3](#T3){ref-type="table"}). Furthermore, IFN-β treatment combined with ifosfamide demonstrated a strong antitumor effect by potently inhibiting tumor growth in ES cells in a xenograft model ([@B164]), by drastically reducing the expression of angiogenesis mediators, including VEGF, matrix metalloproteinase (MMP)-9, and urokinase plasminogen activator receptor (uPAR) ([@B165]).

Vascular Endothelial Cell Growth Factor A (VEGFA)/VEGF and Its Inhibitors {#S3.SS8}
-------------------------------------------------------------------------

Vascular Endothelial Cell Growth Factor A and its ligand VEGF are involved in the pathogenesis of ES. VEGF isoform (VEGF~165~) expression significantly increased cell proliferation and tumor growth in ES cells by stimulating the migration of BM to the tumor, by increasing tumor vessel density ([@B109]). Furthermore, miR-638, which inhibits cell proliferation by targeting Sox-2, suppressed the expression of VEGFA in ES cells through direct targeting ([Figure 2](#F2){ref-type="fig"}; [@B121]; [@B221]). Moreover, the secretion and expression of VEGFA in ES cells were induced by IGF-mediated activation of PI3K/AKT and MAPK signaling pathways ([Figure 1](#F1){ref-type="fig"}; [@B183]).

Additionally, VEGFR inhibitors were evaluated as vascular targeting agents for the treatment of ES ([Table 3](#T3){ref-type="table"}). Apatinib (rivoceranib), a novel VEGFR2 inhibitor, showed stabilized disease symptoms in 19.6% sarcoma patients and a partial response in 62.5% patients. The ORR with apatinib was 70% for ES, 40.9% for osteosarcoma, 100% for chondrosarcoma, and 71.4% for soft tissue sarcoma ([@B212]), indicating that combination therapy with IGF-1R may be therapeutically more efficient for cancer patients.

Following the administration of axitinib, another VEGFR 1--3 inhibitor, 31.25% of recurrent or refractory solid tumor patients, including ES, achieved SD, and 0.07% of patients showed partial response ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02164838) ([@B64]). Additionally, axitinib in combination with pembrolizumab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody for advanced sarcoma patients, demonstrated that 28% of patients achieved SD and 25% showed partial response ([ClinicalTrials.gov](https://clinicaltrials.gov), number NCT02636725) ([@B209]).

Pazopanib is an inhibitor of multiple protein tyrosine kinases, including VEGFR 1-3, c-kit, and PDGFR. In phase 3 clinical trial ([ClinicalTrials.gov](https://clinicaltrials.gov), number: NCT00753688), treatment with pazopanib, a synthetic indazolpyrimidine, revealed a 2.87-fold higher PFS in sarcoma patients when compared with the placebo group. Pazopanib treatment resulted in SD in 67% of patients, demonstrating a partial response in 6% of patients ([@B202]). In metastatic ES patients, the administration of pazopanib produced significant responsiveness with complete tumor regression and prolonged survival for more than 26 months ([@B133]). Moreover, pazopanib maintenance therapy in ES patients, following high-dose chemotherapy with topotecan, significantly prolonged PFS, with near-complete remission for 1 year ([@B188]).

Adnectin, a VEGFR2 inhibitor, in combination with AT580Peg40, an IGF-1R inhibitor, reduced tumor growth by 83.4% in mice by normalizing the microvascular architecture via inhibition of autocrine VEGF-secretion and downregulation of IGF-1R. Moreover, AT580Peg40 and adnectin monotherapies yielded 37.18% and 73.39% tumor growth inhibition, respectively ([@B1]). These monotherapies or a combination therapy presented manageable toxicities; therefore, such therapies can be promising new treatment options.

AXL Receptor Tyrosine Kinase/Gas6 and Its Inhibitors {#S3.SS9}
----------------------------------------------------

AXL receptor tyrosine kinase, together with its ligand, growth-arrest-specific protein 6 (Gas6), is a new therapeutic target overexpressed in various cancers and significantly associated with tumor proliferation, metastasis, EMT, and acquisition of CSC characteristics ([@B63]; [@B223]). Moreover, AXL expression is associated with the pathogenesis of ES. Medium and high levels of AXL were detected in 69% of ES patients ([Table 1](#T1){ref-type="table"}). High AXL expression worsened the survival rate in ES patients. Bemcentinib (BGB324), an AXL inhibitor, in combination with vincristine (a mitotic inhibitor), showed a synergistic therapeutic effect, reducing cell viability and migration of high AXL- and Gas6-expressing ES cells ([Table 3](#T3){ref-type="table"}; [@B57]).

Involvement of Erythropoietin-Producing Hepatoma (EPH), Receptor A2 (EphA2), and c-kit (CD117) Stem Cell Receptor in the Pathogenesis of ES {#S3.SS10}
-------------------------------------------------------------------------------------------------------------------------------------------

The activation of the erythropoietin-producing hepatoma (EPH) receptor A2 (EphA2) is involved in FGF production. EphA2 is highly expressed in ES cells and ES patients. CAV1, an activator of EphA2, increased EphA2 activation through proper localization of EphA2, via the formation of the CAV1/EphA2 complex. CAV1-mediated EphA2 activation suppressed cell death and impaired vascularization in ES xenograft models by increasing the migration of endothelial cells and inducing the expression and secretion of FGF through AKT activation ([Figure 2](#F2){ref-type="fig"}; [@B161]). Phosphorylation at S897 (p-EphA2^*S*897^) of EphA2 correlated with the aggressiveness of ES. High p-EphA2^*S*897^ levels significantly increased the proliferation and migration of ES cells when compared with low phosphorylation levels; however, its mutant markedly suppressed the metastatic potential of ES cells. EphA2 expression was observed in 90.4% of ES patients, and this phosphorylation was associated with a lower survival rate in ES patients. Additionally, EphA2 demonstrated a strong correlation with cellular movement and survival-related signaling, such as the EGFR signaling pathway ([Table 1](#T1){ref-type="table"}; [@B61]).

c-kit (CD117), a tyrosine kinase receptor, plays a crucial role in the development of melanogenesis, hematopoiesis, and gonadogenesis ([@B144]), and is highly expressed in soft tissue sarcoma cells of neuroectodermic origin, such as ES and peripheral neuroectodermal tumors (PNET). Activation of c-kit by its ligand stem cell factor (SCF) subsequently induces cell proliferation ([@B156]). Previously, two separate reports revealed that c-kit was significantly upregulated in 65% of ES patients and 38% of ES patients, respectively ([Table 1](#T1){ref-type="table"}; [@B3]; [@B45]). Another report documented that 71% of ES and 100% of synovial sarcoma patients were positive for c-kit; additionally, 29 and 64% of ES and synovial sarcoma patients showed strong and diffuse staining for c-kit, respectively ([Table 1](#T1){ref-type="table"}; [@B179]). However, treatment with soluble SCF, presenting biological activities distinct from membrane-bound SCF, markedly decreased cell migration, metastasis to the lungs and extrapulmonary sites, and death due to metastasis in mice ([@B106]).

Imatinib inhibits tumor growth of ES cells *in vivo* and *in vitro* by suppressing activation of SCF-mediated c-kit ([@B128]); however, a clinical trial evaluating imatinib failed to demonstrate clinical benefits in patients with ES ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT00154388) ([@B31]). In another study, 14.3% of ES patients exhibited partial response without progression ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT00062205) ([@B28]). Regorafenib treatment, as a multikinase inhibitor, including c-Kit, VEGFR1-3, BRAF, FGFR1, significantly increased the EFS in 100% (9/9) of sarcoma models, including osteosarcoma, rhabdomyosarcoma, and ES ([@B76]), and is currently under evaluation in phase 2 clinical trial for patients with sarcoma subtypes, including ES ([ClinicalTrials.gov](https://clinicaltrials.gov) identifier: NCT02048371).

The Functional Role of Non-Receptor Tyrosine Kinases in ES Progression and on Its Inhibitors {#S4}
============================================================================================

The Janus Kinase (JAK)/Signal Transducer and Activator of Transcription (STAT) and Its Inhibitors {#S4.SS1}
-------------------------------------------------------------------------------------------------

The JAK/STAT pathway plays a major role in the progression of various types of cancers ([@B90]), including ES. STAT3 activation was identified in 51% of ES patients and primary ES cells. However, STAT3 activation failed to correlate with EWS-FLI1 ([@B103]). Another report demonstrated that STAT3 was activated in 58% of ES patients and ES cells ([@B19]). The activation of STAT3 was markedly increased by a W775 stop germline mutation of protein tyrosine phosphatase delta, a tumor suppressor, identified in 37.5% of metastatic ES patients ([@B205]; [@B86]; [@B87]). Treatment with epigallocatechin gallate, major catechin present in green tea, inhibited proliferation, survival, and invasiveness of ES cells by suppressing its downstream pathways, including PI3/AKT, JAK2/STAT3, and by RAS/ERK signaling through the inhibition IGF-1R activation ([@B94]).

The secretion of cytokines enhances the progression of ES. Oncostatin M (OSM), a cytokine of the interleukin-6 (IL-6) family, as well as its receptors, induced cell proliferation in ES cells by activation of STAT3 and Myc ([@B38]). Furthermore, the high levels of IL-6, secreted by ES-stroma crosstalk in ES tumor microenvironment, activated the JAK/STAT3 signaling and inducing resistance to the IGF-1R blockade; however, the combination of IGF-1R and STAT3 inhibitors significantly increased sensitivity against the resistance to IGF-1R ([@B107]; [@B166]).

Janus Kinase/STAT inhibitors have been investigated as monotherapy for the treatment of ES ([Table 3](#T3){ref-type="table"}). ViscumTT treatment, a whole mistletoe extract, significantly reduced tumor growth in ES cells *in vivo* through the JAK/STAT3 pathway and its downstream targets, including BIRC5 and Myc ([@B196]; [@B99]). AZD1480, a JAK1/2 inhibitor, exhibited antitumor activity by inhibiting the growth of ES cells and tumor formation in xenograft models via the suppression of the IL-6/JAK2/STAT3 signaling pathway. Furthermore, AZD1480 treatment significantly increased the survival of ES tumor-bearing xenograft mice ([@B214]). Another small molecule inhibitor, LY5, which inhibits homodimerization by blocking the phosphotyrosine site of the STAT3 SH2 domain, inhibited STAT3 activation by decreasing the cell viability of sarcomas, including osteosarcoma, ES, and RMS. LY5 treatment showed excellent oral bioavailability in both mice and dogs, with 69.5% bioavailability observed following intraperitoneal administration and 78.6% with oral administration. Although treatment with LY5 inhibits the activation of STAT3 in metastatic pulmonary lesions of sarcoma xenografts, it failed to suppress lung metastasis *in vivo* ([@B216]).

Src Family Tyrosine Kinase (SFK) and Its Inhibitors {#S4.SS2}
---------------------------------------------------

In cancer pathogenesis, SFK is essential for growth and metastasis ([@B98]) and its roles have been well established in cancer, with several studies reporting the functional role of SFK in the pathogenesis of ES. Although Src is highly expressed and activated in ES cells and ES patients, its expression demonstrated no significant correlation with histologic subtypes. Dasatinib, an Src inhibitor, induced apoptosis and reduced the invasiveness of ES cells by suppressing the downstream signaling pathways, such as FAK and p130^*CAS*^, via inhibition of Src activity ([Figure 1](#F1){ref-type="fig"}; [@B177]). Using ES cells, phosphoproteomics has shown that SFK is an abundant phosphorylated tyrosine kinase, and dasatinib treatment markedly reduced cell viability in ES cells by inhibiting the activation of PDGFRα and Src ([@B14]). Furthermore, peptide-based tyrosine kinase array revealed that Src is highly expressed and phosphorylated in *CIC-DUX4* sarcoma (CDS) patient-derived xenografts, which is a high-grade Ewing-like small round cell sarcoma ([@B145]). Lyn, a member of SFK, was upregulated and activated in 86.7% of ES patients and ES cells ([Table 1](#T1){ref-type="table"}). However, the downregulation of SFK and treatment with AP23994, an SFK inhibitor, suppressed tumor growth, bone tumor lysis, and metastases in ES cells and the xenograft model ([@B72]). Microenvironmental stress, including growth constraints, serum deprivation, and hypoxia, induced the invasiveness of ES cells through the formation of invadopodia by Src activation, not through the induction of EMT markers and cell proliferation ([@B15]).

Secretion of the extracellular matrix protein, tenascin C, upon microenvironmental stress, induced cell-cell interaction, and growth of ES cells by promoting invadopodia formation by Src activation. In contrast, dasatinib treatment suppressed the environmental stress-mediated invasiveness of ES cells by blocking invadopodia formation associated with Src activation and tenascin ([@B15]; [@B77]). SI221, a new pyrazolo\[3,4-*d*\]pyrimidine SFK inhibitor, reduced cell proliferation and migration of ES cells by inhibiting NOTCH1 cleavage and activating P38 MAPK ([@B83]). Additionally, dasatinib has been evaluated in phase 2 clinical trial in sarcoma patients ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT00464620), revealing that the 6 month PFS rate was 48%, and more than 50% of patients with alveolar soft part sarcoma (ASPS) and epithelioid sarcoma showed disease-free progression for more than 6 months ([@B168]). Furthermore, dasatinib, in combination with other conventional agents (ifosfamide, carboplatin, and etoposide), ids currently under investigation in phases 1 and 2 trials for patients with solid tumors, including sarcoma ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT00788125).

Focal Adhesion Kinase (FAK) and Its Inhibitors {#S4.SS3}
----------------------------------------------

Focal adhesion kinase has been identified as a therapeutic target for cancer, inducing tumor growth, metastasis, acquisition of CSC traits, and drug resistance ([@B185]; [@B215]). FAK is significantly upregulated in ES cells ([@B135]) and highly activated in ES patients and ES cells. Loss of FAK and treatment with a FAK inhibitor (PF-562271) suppressed tumor growth and the invasion ability of ES cells *in vivo* and *in vitro* by suppressing Crkl-associated substrate (CAS) activity and the AKT/mTOR pathway ([@B34]). EWS-FLI1-mediated upregulation of ezrin enhanced the viability and invasion of ES cells via FAK activation ([@B181]). Furthermore, the upregulation of ERBB4 in metastatic ES patients was closely associated with poor survival in ES patients, and ERBB4-mediated activation of the PI3K/AKT/FAK/RAC1 pathway promoted the metastatic capacity of ES cells ([@B126]).

Moreover, rapamycin treatment or loss of TORC1 and TORC2, as mTOR complexes, markedly reduced IGF-1-mediated activation of FAK in ES cells ([@B114]). Furthermore, aurora kinase B (AURKB) inhibitors have been identified as a synergistic drug in combination with FAK inhibitors by utilizing high-throughput drug combination screening, with AURKB highly expressed in ES patients and ES cells. AURKB inhibitor significantly suppressed cell viability, and the combination of the FAK and AURKB inhibitors demonstrated synergistic activity by inhibiting activation of the mTOR pathway ([@B206]).

Clinical activity of GSK2256098, a FAK inhibitor, has been evaluated in cancer patients. GSK2256098 monotherapy was well-tolerated in patients with relapsed glioblastoma, and SD was observed in 27% (3/11) of patients ([ClinicalTrials.gov](https://clinicaltrials.gov): NCT01138033) ([@B26]). In patients with mesothelioma or solid tumors, combination treatment with GSK2256098 and trametinib, a MEK inhibitor, demonstrated that 38% (13/34) of patients presented SD and 50% (3/6) patients demonstrated more than a 70% decrease in phosphorylated FAK/FAK ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT01938443) ([@B122]). Another FAK inhibitor, defatinib (VS-6063), was well-tolerated to patients with solid tumors, with 33% (3/9) patients presenting SD ([@B176]). The combination of defatinib with RO5126766 (RAF/MEK inhibitor) or pembrolizumab (PD-1 blocking antibody) is currently under evaluation for patients with solid tumors ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT03875820, NCT02546531, NCT02758587), but remains to be evaluated in ES patients.

Other Non-receptor Tyrosine Kinases in the Pathogenesis of ES {#S4.SS4}
-------------------------------------------------------------

Activation of ERK 1 and 2 by EWS/FLI-1 induces the transformation of cells. Moreover, a dominant-negative RAS and EWS/FLI-1 mutant, defective in DNA-binding and transcriptional activation, significantly decreased activation of ERK1/2 and transformation of cells ([@B178]).

The C-terminal portion of proline-rich tyrosine kinase (PYK2), involved in the pathogenesis of many cancers, interacts with the N-terminal region (1-233 amino acid) of EWS and eventually regulates G-protein-coupled receptor signaling ([@B54]). Additionally, suppression of PYK2 activity inhibited the AKT/mTOR pathway ([@B34]).

Previous studies have demonstrated that activation of spleen tyrosine kinase (SYK) increases the risk of chemotherapy failure or relapse of B cell acute lymphoblastic leukemia (B-ALL) ([@B151]), and its inhibitors, PRT318 and P505-15, inhibited the survival and migration of chronic lymphocytic leukemia (CLL) by blocking the activation of chemokine receptors (CXCR4, CXCR5) and SYK ([@B79]). SYK was identified as a clinical target through a high-throughput approach using a siRNA library and a small-molecule library, and was reportedly activated in 40% of ES patients ([Table 1](#T1){ref-type="table"}). SYK enhanced cell survival and tumor growth in xenografts. Additionally, MALAT1, a non-coding RNA, transcriptionally activated through SYK/c-MYC pathway, enhanced the malignant traits of ES cells; however, its inhibitors suppressed cell viability and tumor formation in ES cells *in vivo* and *in vitro* via the inhibition of the AKT pathway ([Figure 1](#F1){ref-type="fig"}; [@B186]).

Conclusion {#S5}
==========

Recent studies have demonstrated that activation of several tyrosine kinases, identified as potential therapeutic targets, enhances tumor growth and metastasis, developing chemoresistance in ES cells through the activation of various intracellular downstream signaling pathways. Moreover, drugs targeting specific tyrosine kinases have been developed and approved. Although clinical observations and preclinical trials have reported that monotherapy, as well as combination therapy with such inhibitors, can efficiently combat ES, further investigations with novel multifaceted therapeutic strategies are required. IGF-1R directed therapies have demonstrated only modest efficacy in ES patients; monotherapy and combination therapy with tyrosine kinase inhibitors remain under evaluation. Additionally, the inhibition of kinase activity in ES reduced the sensitivity to the tyrosine kinase inhibitor by developing resistance. Cancer cells acquire drug resistance via mutations that abrogate inhibitor binding. These mutations upregulate oncogenes and activate alternative kinase pathways via compensatory cross-signaling through the tyrosine kinase-induced activation of target networks. The subsequent development of therapeutic resistance to cancer increases the evasion of tyrosine kinase inhibitors ([@B218]). Additional mutations on resistant mutants, to inhibit the developed drug resistance, can increase their sensitivity to cancer cells and prolong patient survival ([@B56]). Several strategies have been proposed to overcome drug-resistant mutations by developing inhibitors such as nilotinib and dasatinib, which possess increased affinity to the ATP binding site and can recognize active conformations of tyrosine kinase. These two compounds have high cellular activity and inhibit all known BCR-ABL1 mutants ([@B208]; [@B95]; [@B218]; [@B56]).

Adoptive cell therapy and a combination of tyrosine kinase targeting agents, along with other conventional agents, may provide novel options to cancer patients to overcome drug resistance and optimize their efficacy and cytotoxicity. The FDA has approved axicabtagene ciloleucel and tisagenlecleucel as CD19 targeting CAR-T cell immunotherapy in patients with B cell lymphoma and acute lymphoblastic leukemia; these agents have shown a safe and improved clinical outcome in the treatment of cancer patients ([@B42]). Currently, CAT-T cell immunotherapy is under evaluation in clinical trials for ES patients presenting sarcoma-specific surface antigens targeting next-generation CAR-T (NCT03356782), GD2-CAR-T (NCT03635632), and EGFR806-CAR-T immunotherapy (NCT03618381). Additionally, histone deacetylase (HDAC) inhibitors, in combination with other conventional agents, have exhibited anticancer effects in preclinical and clinical studies ([@B187]). Vorinostat, in combination with vincristine, irinotecan, and temozolomide, is now under evaluation for ES patients ([ClinicalTrials.gov](https://clinicaltrials.gov) Identifier: NCT04308330). Moreover, significant advances in understanding the functioning of tyrosine kinases in cancer, including identification of molecular mechanisms and the association between tyrosine kinases and the pathogenesis of ES will provide new insights for the selection of novel targets and to further overcome challenges associated with existing treatment strategies for ES. Furthermore, understanding the tumor-initiating abilities of tyrosine kinases and developing strategies to maintain this crucial property will increase success rates and improve outcomes in cancer therapy.
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